British scientists have identified biological markers in the blood which should help doctors match patients to the best type of treatment for depression.
The aim is to end the “trial and error” prescription of antidepressants, which is often the only way depressed patients can find the most effective treatment, said researchers regarding what they described as a small but promising study.
“The study shows that we could use a blood-based “test” to personalize the treatment of depression,” said Carmine Pariante of King’s College London’s Institute of Psychiatry, who led the study.
She and colleagues found that high levels of inflammation – which show up in biological markers in the blood – are part of the mechanism leading to depression, especially to particular forms of the condition that do not respond well to mild or low-dose antidepressants.
“If a patient had high levels of inflammation, they could immediately begin with a more intensive treatment program, such as combining antidepressants or stepping up the doses,” Pariante said.
A MAJOR PROBLEM
Major depression affects around 20 percent of people at some point in their lives. The World Health Organisation (WHO)predicts that by 2020, depression will rival heart disease as the health disorder with the highest global disease burden.
While there are many antidepressants on the market, including top sellers such as Prozac and Seroxat, it is widely accepted that many antidepressants work in only half of patients half of the time, and drugmakers are struggling to come up with a new generation of drugs in this field.
In the study published on Wednesday in the journal Neuropsychopharmacology, Pariante’s team set out to try to identify two types of biomarkers – ones which could predict future response to antidepressants, called predictors, and others which are targeted by antidepressants and change over the course of treatment, called targets.
The researchers explained that in human cells, information from genes is transcribed into so-called messenger RNA, or mRNA, before it becomes visible as a physical or biochemical sign. So the team monitored the patients’ mRNA before and after they were treated with one of two antidepressants – escitalopram or nortriptyline.
Escitalopram, sold under various brand names including Lexapro, Seroplex, Cipralex and made by generic drugmakers, is a serotonin reuptake inhibitor (SSRI).
Nortriptyline, sold under the brand names Sensoval, Aventyl and others, is an older type of antidepressant known as a tricyclic. They are both commonly prescribed as first line antidepressant treatments in Britain and other countries.
After 8 weeks of treatment, the researchers found that patients who were not getting any better were ones who had significantly higher levels of three inflammation markers before treatment started.
This suggests these three signals could be used to find patients who are least likely to respond to antidepressants, allowing doctors to consider a more tailored or “personalized” approach to treatment from the start, the researchers said.
“This is a small study, but the findings are promising,” they said in a statement. “Personalized treatments for depression could help us avoid the current ‘trial and error’ way of prescribing antidepressant medication.”
Reuters
